Loading organizations...
TandemAI provides an integrated drug discovery platform, unifying AI and physics-based computational methods with in-house wet lab operations. This solution streamlines research workflows, allowing scientists to leverage advanced technologies for discovery and validation. Its TandemViz user interface offers cloud-enabled high-performance computation and consolidated data management.
Co-founded by CEO Jeff He and computational drug discovery veteran Lanny Sun, TandemAI emerged from the insight to integrate disparate technologies into an accessible infrastructure. Sun's prior success with Silicon Therapeutics informed their aim to bridge advanced computational power with practical experimental workflows, establishing a unified approach.
TandemAI supports a global base of biopharmaceutical clients, accelerating research. Its vision is to transform drug discovery by democratizing advanced computational technologies and reimagining infrastructure. Through its integrated platform, TandemAI empowers the scientific community to pursue innovative drug development efficiently.
TandemAI has raised $82.0M across 3 funding rounds.
TandemAI has raised $82.0M in total across 3 funding rounds.
TandemAI is a technology company that builds an integrated drug discovery platform combining AI-driven technologies, physics-based computational methods, high-performance computing, and in-house wet lab operations to accelerate preclinical drug development.[1][2][3][4] It serves over 80 biotech and pharma clients worldwide, solving the problem of high barriers to advanced tools by democratizing access through a user-friendly, cloud-based interface called TandemViz, streamlined pricing, and end-to-end solutions that improve therapeutic candidate success rates.[1][3][5][6] With over 350 employees, including 50+ top AI and computational chemistry experts, TandemAI has shown strong growth, raising $35M in Series A (2023) and $22M extension (November 2025), expanding wet lab capacity, and merging with Perpetual Medicines in July 2025.[3][6][8]
TandemAI was founded in late 2021 by Jeff He (MBA, Co-Founder and CEO) and Albert Pan (Ph.D., Co-Founder and Executive Chairman), both with deep expertise in AI, computational chemistry, and drug discovery infrastructure.[1][3] The idea emerged from recognizing barriers to advanced tools like physics-based simulations, AI models, and supercomputing, aiming to integrate them with wet labs for efficient, accessible drug discovery.[3][4] Early traction was rapid: within 15 months, it grew to ~50 clients, secured $35M Series A from investors like Qiming Venture Partners and Eight Roads (with Kan Chen joining the board), and expanded operations in the U.S. and China.[3] This momentum continued with a $22M Series A extension in November 2025 and a strategic merger with Perpetual Medicines in July 2025 to bolster physics and AI capabilities.[6][8]
TandemAI rides the AI-drug discovery wave, where computational tools promise to cut preclinical timelines and costs amid rising drug development failures (often >90% attrition rates).[3][6] Timing is ideal post-2021 AI boom, with market forces like biotech funding recovery, China-U.S. innovation hubs, and demand for integrated CROs favoring its dual-market presence (Shanghai, New York).[4] It influences the ecosystem by lowering entry barriers for smaller biotechs, fostering open-source collaboration, and enabling scalable innovation—evident in its 80+ clients and mergers like Perpetual Medicines, which amplify physics-AI synergies.[1][6][7]
TandemAI is poised to dominate integrated AI-physics drug discovery, leveraging its $57M+ Series A funding to scale wet labs, refine TandemViz, and pursue more mergers/acquisitions.[3][6][8] Trends like generative AI for molecules, multimodal data integration, and global CRO consolidation will propel growth, potentially capturing share from traditional players. Its influence may evolve into a platform leader, powering breakthroughs for underserved therapeutics and redefining accessible R&D—transforming how the world discovers life-saving drugs, just as its mission promised from day one.[1][3]
TandemAI has raised $82.0M in total across 3 funding rounds.
TandemAI's investors include KHK & Partners, peter zhao, Chen Kan, F-Prime Capital Partners, Jarlon Tsang, Chong Xu, OrbiMed, David Wang, Chengwei Capital.
TandemAI has raised $82.0M across 3 funding rounds. Most recently, it raised $22.0M Series A Extension in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 14, 2025 | $22M Series A Plus | — | KHK & Partners, Peter Zhao | Announced |
| Feb 1, 2023 | $35M Series A | Chen KAN | F Prime Capital, Jarlon Tsang, Chong XU, OrbiMed | Announced |
| Dec 23, 2021 | $25M Pre Seed | David Wang, Chengwei Capital | — | Announced |